Target intelligence / Profile preview

Taste receptor type 2 member 3 (TAS2R3)

Target
TAS2R3
Molecular classification
G protein-coupled receptor (GPCR), Receptor, 7-transmembrane receptor protein, Bitter taste receptor
01

Overview

Taste receptor type 2 member 3 (TAS2R3) is a bitter taste receptor belonging to the G protein-coupled receptor (GPCR) superfamily, encoded by an intronless gene that is primarily expressed in taste receptor cells of the tongue and palate[1][2]. It detects bitter compounds in food and is involved in the transduction of taste signals via gustducin-mediated pathways, using downstream effectors such as PLCβ2 and TRPM5[1][4]. TAS2R3, like other TAS2Rs, is also found in various extraoral tissues, where it may modulate physiological processes including immunity, metabolism, and possibly the risk of certain diseases (e.g. thyroid cancer)[2][5]. The receptor responds to a variety of bitter substances, and genetic variations in TAS2R3 are linked to individual differences in bitter taste perception and disease susceptibility[2][4]. As a member of a large family of bitter taste receptors, TAS2R3 plays a role in chemosensory detection of noxious environmental compounds, as well as in extraoral defense and regulation mechanisms[2][4][5].

Other names
TAS2R3T2R3Taste 2 receptor member 3Candidate taste receptor T2R3Taste receptor, type 2, member 3
02

Mechanism of action

Agonists: Activate GPCR pathway, leading to PLCβ2 and TRPM5 signaling, resulting in cell depolarization and taste/chemosensory perception - In extraoral tissues: Same pathway may activate local hormonal, metabolic, or immune responses

03

Biological functions

Perception of bitter taste (bitter compound detection)Signal transduction (via GPCR pathway, gustducin-coupled)Sensory perception of tastePossible regulation of metabolism and hormone secretion in extraoral tissuesInnate immunity functions in extraoral tissues (defense mechanisms)
04

Disease associations

Modulation of cancer risk (e.g. reduced susceptibility to papillary thyroid carcinoma)Possibly other roles through extraoral expression in immunity and metabolism
05

Safety considerations

No direct safety concerns as therapeutic targets are well-documented; broad expression may contribute to off-target effects if systemically targetedGPCRs are generally considered druggable but specificity within taste receptor family is challenging
06

Interacting drugs

Chloroquine

3 more in the full profile.

07

Biomarkers

Genetic variants (e.g. rs2270009) as markers for altered thyroid cancer risk and bitterness perceptionPolymorphisms modulating taste sensitivity

Beyond the preview

Go deeper on Taste receptor type 2 member 3 (TAS2R3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Taste receptor type 2 member 3 (TAS2R3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call